Last reviewed · How we verify
Carfilzomib and Dexamethasone — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Carfilzomib and Dexamethasone (Carfilzomib and Dexamethasone) — Oncotherapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Carfilzomib and Dexamethasone TARGET | Carfilzomib and Dexamethasone | Oncotherapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Carfilzomib and Dexamethasone CI watch — RSS
- Carfilzomib and Dexamethasone CI watch — Atom
- Carfilzomib and Dexamethasone CI watch — JSON
- Carfilzomib and Dexamethasone alone — RSS
Cite this brief
Drug Landscape (2026). Carfilzomib and Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/carfilzomib-and-dexamethasone. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab